Inventor · disambiguated record
Leona E. Ling
Also filed as: LING LEONA · LING LEONA E
14 granted patents·14 pending applications·50 citations·filing 2001–2024
90Inventor score
Top patents by PatentIndex Score
28 records- 0194US10676526B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2016·Granted Jun 9, 2020·9 cites·19 claims
- 0292US11124573B2Compositions and methods related to engineered Fc constructsMOMENTA PHARMACEUTICALS INC·Filed 2019·Granted Sep 21, 2021·6 cites·40 claims
- 0392US10239944B2Compositions and methods related to engineered Fc constructsMOMENTA PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·13 cites·24 claims
- 0489US11352415B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·4 cites·5 claims
- 0587US11345751B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2017·Granted May 31, 2022·4 cites·40 claims
- 0686US11661456B2Sialylated glycoproteinsMOMENTA PHARMACEUTICALS INC·Filed 2018·Granted May 30, 2023·4 cites·4 claims
- 0785US10464996B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2014·Granted Nov 5, 2019·7 cites·6 claims
- 0884US2025011432A1COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc CONSTRUCTSMOMENTA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0983US11732047B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·1 cites·26 claims
- 1079US12297256B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2022·Granted May 13, 2025·0 cites·16 claims
- 1178US12163951B2Methods for predicting response to treatmentMOMENTA PHARMACEUTICALS INC·Filed 2023·Granted Dec 10, 2024·0 cites·10 claims
- 1278US2024158508A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1376US2024052040A1Sialylated GlycoproteinsMOMENTA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1475US11639923B2Methods for predicting response to treatmentMOMENTA PHARMACEUTICALS INC·Filed 2018·Granted May 2, 2023·1 cites·10 claims
- 1574US12071482B2Compositions and methods related to engineered Fc constructsMOMENTA PHARMACEUTICALS INC·Filed 2021·Granted Aug 27, 2024·0 cites·13 claims
- 1668US11773168B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2018·Granted Oct 3, 2023·1 cites·13 claims
- 1765US2020087402A1Sialylated GlycoproteinsMOMENTA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1864US2023049725A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1962US2024158509A1Fcrn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2061US2016257754A1Sialylated glycoproteinsMOMENTA PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 2158US2010183560A1Angiogenesis-modulating compositions and usesCURIS INC·Filed 2009·Application pending·0 cites
- 2256US2021116462A1Methods and Compositions for the Diagnosis and Treatment of Kawasaki DiseaseMOMENTA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2350US2017052200A1Methods and compositions for the diagnosis and treatment of kawasaki diseaseMOMENTA PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 2450US2022144946A1Fcrn antibodies and methods of use thereofJANSSEN BIOTECH INC·Filed 2021·Application pending·0 cites
- 2544US2003022819A1Angiogenesis-modulating compositions and usesFiled 2001·Application pending·0 cites
- 2643US2006264440A1Pyrazoles and methods of making and using the sameBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 2741US2019048417A1Therapeutic and Diagnostic Methods for Autoimmune Diseases and/or InflammationMOMENTA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 2840US12391759B2Methods related to engineered Fc constructsMOMENTA PHARMACEUTICALS INC·Filed 2017·Granted Aug 19, 2025·0 cites·3 claims
Join the waitlist — get patent alerts
Get an alert when Leona E. Ling files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →